[Mechanism of action of biological disease--modifying antirheumatic drugs].
Nobunori
N
Takahashi
Naoki
N
Ishiguro
D000069594:Abatacept / Q000494:pharmacology / Q000627:therapeutic use; D000068879:Adalimumab / Q000494:pharmacology / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000494:pharmacology* / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology; D000068582:Certolizumab Pegol / Q000494:pharmacology / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D000068800:Etanercept / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D015850:Interleukin-6 / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D000069594:Abatacept; D000068879:Adalimumab; C502936:tocilizumab; D000068800:Etanercept; D000068582:Certolizumab Pegol